KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Acquisitions & Divestments (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Change in Acquisitions & Divestments data on record, last reported at $105.8 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 5.45% year-over-year to $105.8 million; the TTM value through Dec 2025 reached $493.5 million, up 50.21%, while the annual FY2025 figure was $493.5 million, 50.21% up from the prior year.
  • Change in Acquisitions & Divestments reached $105.8 million in Q4 2025 per ACAD's latest filing, down from $125.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $259.4 million in Q1 2023 and bottomed at $7.5 million in Q2 2023.
  • Average Change in Acquisitions & Divestments over 5 years is $105.6 million, with a median of $104.8 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 89.22% in 2023, then surged 986.67% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $110.5 million in 2021, then crashed by 31.4% to $75.8 million in 2022, then soared by 36.89% to $103.8 million in 2023, then grew by 7.8% to $111.8 million in 2024, then fell by 5.45% to $105.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $105.8 million in Q4 2025, $125.6 million in Q3 2025, and $131.4 million in Q2 2025.